FDA clears IND for SAB Biotherapeutics' T1D therapy SAB-142 Phase 1 trial

SAB Biotherapeutics, Inc.

FDA cleared IND for SAB-142, a human anti-thymocyte immunoglobulin for type 1 diabetes.
Phase 1 HUMAN trial is randomized, double-blind, placebo-controlled, single-ascending dose (0.03-2.5 mg/kg).
Enrollment of US patients with type 1 diabetes now permitted; third cohort dosed with no serum sickness.
Topline results from the MELD-ATG study expected in 2025.
SAB-142 aims to delay onset or progression of stage 3 type 1 diabetes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.